Brief: Paratek Pharma - The Lancet Infectious Diseases Publishes Results From Paratek’S Phase 3 Oral Only Dosing Study Of Nuzyra (Omadacycline) For Skin Infections
30/08/2019 13:17
Aug 30 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* THE LANCET INFECTIOUS DISEASES PUBLISHES RESULTS FROM
PARATEK’S
PHASE 3 ORAL ONLY DOSING STUDY OF NUZYRA® (OMADACYCLINE) FOR
SKIN INFECTIONS
* PARATEK PHARMACEUTICALS INC - ONCE-DAILY, ORAL NUZYRA MET
ALL
PRIMARY AND SECONDARY CLINICAL STUDY ENDPOINTS
* PARATEK PHARMACEUTICALS INC - ORAL NUZYRA WAS SHOWN TO BE
SAFE
AND EFFECTIVE FOR TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN
STRUCTURE INFECTIONS
Source text for Eikon: ID:nGNXbt3YqZ
Further company coverage: PRTK.O
((Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million